Research Use Only. KIRhub outputs are computational research artifacts. They are not validated for clinical decision-making, diagnosis, or treatment.

← Cohorts · lung-landscapes@6

SRR6013588

— · cohortA1

3ac96b01-ab9e-5f70-9be5-aa595cebba6f

Score in workbench →

Clinical attributes

From the source cohort, normalized into canonical keys plus the project's native columns.

cancer_type
—
cancer_type_detailed
—
subtype
cohortA1
subtype
cohortA1

GSVA pathway preview (50 Hallmark scores)

MeasuredDerivedReference

Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.

Top 10 elevated

  • HEDGEHOG_SIGNALING+0.340
  • TGF_BETA_SIGNALING+0.300
  • APICAL_JUNCTION+0.240
  • ADIPOGENESIS+0.230
  • UV_RESPONSE_DN+0.230
  • INTERFERON_ALPHA_RESPONSE+0.220
  • WNT_BETA_CATENIN_SIGNALING+0.190
  • NOTCH_SIGNALING+0.180
  • MYOGENESIS+0.170
  • BILE_ACID_METABOLISM+0.150

Top 10 suppressed

  • E2F_TARGETS-0.480
  • MYC_TARGETS_V2-0.480
  • PANCREAS_BETA_CELLS-0.470
  • MYC_TARGETS_V1-0.460
  • G2M_CHECKPOINT-0.450
  • MTORC1_SIGNALING-0.400
  • SPERMATOGENESIS-0.340
  • GLYCOLYSIS-0.320
  • UNFOLDED_PROTEIN_RESPONSE-0.280
  • TNFA_SIGNALING_VIA_NFKB-0.250

Patient twins — nearest pathway neighbors

MeasuredDerived

10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.

10 twins match this tumor's tissue · 0 come from a different tissue of origin

#SampleCancer typeSubtypecos similarity
1TCGA-97-8172-01A-11R-2287-07
lung-landscapes@6
—cohortA10.835
2SRR6013595
lung-landscapes@6
—cohortA10.821
3SRR6013583
lung-landscapes@6
—cohortA10.795
4TCGA-97-8174-01A-11R-2287-07
lung-landscapes@6
—cohortA20.793
5TCGA-55-7573-01A-11R-2039-07
lung-landscapes@6
—cohortA10.788
6SRR6013574
lung-landscapes@6
—cohortA10.784
7TCGA-86-8280-01A-11R-2287-07
lung-landscapes@6
—cohortA10.781
8TCGA-44-5645-01A-01R-1628-07
lung-landscapes@6
—cohortA10.771
9SRR1516071
bladder-landscape@3
——0.764
10MNG695
mng-umap@100
——0.763

Per-pathway drug coverage

ModeledCalibratedDerived

For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.

0 of 20 elevated pathways have at least one drug that meaningfully reverses them.

Pathway (elevated)tumor scoreBest drugreversal magnitude
HEDGEHOG_SIGNALING0.340Inavolisib— uncovered
TGF_BETA_SIGNALING0.300Inavolisib— uncovered
APICAL_JUNCTION0.240Inavolisib— uncovered
ADIPOGENESIS0.230Inavolisib— uncovered
UV_RESPONSE_DN0.230Inavolisib— uncovered
INTERFERON_ALPHA_RESPONSE0.220Inavolisib— uncovered
WNT_BETA_CATENIN_SIGNALING0.190Inavolisib— uncovered
NOTCH_SIGNALING0.180Inavolisib— uncovered
MYOGENESIS0.170Inavolisib— uncovered
BILE_ACID_METABOLISM0.150Inavolisib— uncovered
FATTY_ACID_METABOLISM0.150Inavolisib— uncovered
IL2_STAT5_SIGNALING0.130Idelalisib— uncovered
PEROXISOME0.090Idelalisib— uncovered
PI3K_AKT_MTOR_SIGNALING0.090Inavolisib— uncovered
HEME_METABOLISM0.050Temsirolimus— uncovered
XENOBIOTIC_METABOLISM0.030Inavolisib— uncovered
INTERFERON_GAMMA_RESPONSE0.020Idelalisib— uncovered
MITOTIC_SPINDLE0.020Inavolisib— uncovered
COMPLEMENT0.010Inavolisib— uncovered
KRAS_SIGNALING_UP0.010Inavolisib— uncovered